Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell of lymphatic vessel | 19 studies | 32% ± 10% | |
endothelial cell | 8 studies | 24% ± 9% | |
fibroblast | 7 studies | 22% ± 6% | |
macrophage | 7 studies | 22% ± 7% | |
non-classical monocyte | 4 studies | 30% ± 12% | |
epithelial cell | 4 studies | 19% ± 3% | |
plasmacytoid dendritic cell | 4 studies | 20% ± 2% | |
plasmablast | 3 studies | 43% ± 7% | |
B cell | 3 studies | 18% ± 3% | |
classical monocyte | 3 studies | 22% ± 4% | |
basal cell | 3 studies | 20% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 19% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1288.99 | 1445 / 1445 | 100% | 11.63 | 183 / 183 |
stomach | 100% | 910.56 | 359 / 359 | 100% | 11.91 | 286 / 286 |
lung | 100% | 1342.12 | 578 / 578 | 100% | 13.23 | 1153 / 1155 |
prostate | 100% | 1322.89 | 245 / 245 | 100% | 14.94 | 501 / 502 |
skin | 100% | 1415.41 | 1808 / 1809 | 100% | 19.59 | 471 / 472 |
breast | 100% | 1724.01 | 459 / 459 | 100% | 19.23 | 1115 / 1118 |
ovary | 100% | 1179.59 | 180 / 180 | 100% | 12.51 | 428 / 430 |
bladder | 100% | 1604.81 | 21 / 21 | 99% | 20.95 | 501 / 504 |
intestine | 100% | 1351.17 | 966 / 966 | 99% | 11.55 | 523 / 527 |
uterus | 100% | 1275.66 | 170 / 170 | 99% | 16.23 | 454 / 459 |
kidney | 100% | 1008.81 | 89 / 89 | 99% | 15.47 | 890 / 901 |
brain | 99% | 790.96 | 2626 / 2642 | 99% | 8.07 | 695 / 705 |
thymus | 100% | 912.19 | 652 / 653 | 98% | 8.95 | 591 / 605 |
liver | 97% | 525.75 | 219 / 226 | 96% | 12.37 | 390 / 406 |
pancreas | 91% | 379.29 | 297 / 328 | 98% | 13.47 | 175 / 178 |
adrenal gland | 98% | 631.57 | 254 / 258 | 90% | 7.43 | 207 / 230 |
adipose | 100% | 2039.25 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1435.53 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 23.77 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 13.54 | 29 / 29 |
spleen | 100% | 1158.27 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.09 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.23 | 1 / 1 |
peripheral blood | 100% | 940.28 | 927 / 929 | 0% | 0 | 0 / 0 |
muscle | 100% | 844.00 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 716.70 | 849 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007613 | Biological process | memory |
GO_0008344 | Biological process | adult locomotory behavior |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008418 | Molecular function | protein-N-terminal asparagine amidohydrolase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NTAN1 |
Protein name | N-terminal asparagine amidase (Protein N-terminal asparagine amidohydrolase) Protein N-terminal asparagine amidohydrolase (EC 3.5.1.121) (Protein NH2-terminal asparagine amidohydrolase) (PNAA) (Protein NH2-terminal asparagine deamidase) (PNAD) (Protein N-terminal Asn amidase) (Protein N-terminal asparagine amidase) (Protein NTN-amidase) |
Synonyms | |
Description | FUNCTION: N-terminal asparagine deamidase that mediates deamidation of N-terminal asparagine residues to aspartate. Required for the ubiquitin-dependent turnover of intracellular proteins that initiate with Met-Asn. These proteins are acetylated on the retained initiator methionine and can subsequently be modified by the removal of N-acetyl methionine by acylaminoacid hydrolase (AAH). Conversion of the resulting N-terminal asparagine to aspartate by NTAN1/PNAD renders the protein susceptible to arginylation, polyubiquitination and degradation as specified by the N-end rule. This enzyme does not act on substrates with internal or C-terminal asparagines and does not act on glutamine residues in any position, nor on acetylated N-terminal peptidyl Asn. . |
Accessions | ENST00000634013.1 H3BMX8 ENST00000631580.1 ENST00000622833.4 ENST00000624579.3 ENST00000614882.2 ENST00000568320.5 ENST00000633231.1 Q96AB6 H3BPN7 ENST00000568738.1 H3BR97 ENST00000287706.8 ENST00000620176.4 H3BU50 ENST00000615632.4 ENST00000563940.1 ENST00000633749.1 A0A087X0T5 ENST00000565187.5 H3BNJ5 ENST00000566419.1 |